Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society - Scorecard - MDSpire
Advertisement
Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society
Clinical Scorecard: Guidelines for the Diagnosis and Treatment of Hidradenitis Suppurativa in the UAE: A Consensus from the Emirates Dermatology Society
At a Glance
Category
Detail
Condition
Hidradenitis Suppurativa (HS)
Key Mechanisms
Chronic inflammatory condition of the pilosebaceous unit, often linked to metabolic comorbidities.
Target Population
Patients with hidradenitis suppurativa in the United Arab Emirates.
Care Setting
Multidisciplinary care settings, including dermatology and psychological support.
Key Highlights
Emphasizes early intervention and lifestyle modification.
Incorporates a stepwise treatment approach: topical agents, systemic antibiotics, biologics, and surgical options.
Addresses the significant mental health impact of HS, including depression and anxiety.
Aims to standardize care and improve treatment outcomes across the UAE.
Highlights the need for coordination among interdisciplinary centers.
Guideline-Based Recommendations
Diagnosis
HS is primarily a clinical diagnosis with an average diagnostic delay of 7.2–10 years.
Management
Utilize a stepwise approach tailored to disease severity, including topical agents, systemic antibiotics, biologics, and surgical options.
Monitoring & Follow-up
Regular screening for comorbidities, particularly metabolic conditions.
Risks
HS is associated with significant mental health issues and impaired quality of life.
Patient & Prescribing Data
Individuals diagnosed with hidradenitis suppurativa in the UAE.
Management should be individualized based on disease severity and patient needs.
Clinical Best Practices
Implement multidisciplinary care including psychological support.
Encourage lifestyle modifications to mitigate disease impact.
Facilitate coordination among care providers to enhance treatment outcomes.
Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.
